Swedish inhaled product developer Iconovo has announced a deal with Japanese pharmaceutical company TOA for development of Iconovo's ICOone unit dose dry powder inhaler for the treatment of asthma and COPD. TOA's Nishihongo facility includes a building dedicated to DPI manufacturing and filling that has been in operation since 2007. According to Iconovo, the … [Read more...] about Iconovo extends deal with TOA, will develop DPI for the Japanese market
News
UCB acquires midazolam nasal spray from Proximagen
Belgian pharmaceutical company UCB has acquired the rights to Proximagen's USL261 midazolam nasal spray for $150 million up front and potential milestone payments of up to $220 million, the company said. An NDA for USL261 is expected to be filed by the end of 2018. Proximagen, a former subsidiary of Upsher-Smith, reported positive Phase 3 results for USL261 in … [Read more...] about UCB acquires midazolam nasal spray from Proximagen
Copley Scientific’s Mark Copley answers questions about USP Chapter <1602>
Copley Scientific CEO Mark Copley discusses the recently published USP Chapter <1602> for testing "Spacers & Valved Holding Chambers Used with Inhalation Aerosols" Q: What does this new USP Chapter cover? A: Chapter <1602>, published by the United States Pharmacopeia (USP) in 2017, defines standardized methods for characterizing the in vitro … [Read more...] about Copley Scientific’s Mark Copley answers questions about USP Chapter <1602>
Inhalation Sciences names Lena Heffler as CEO
Swedish instrument company Inhalation Sciences has announced the appointment of Lena Heffler as its new CEO effective May 7, 2018. She will succeed Fredrik Sjövall, who is expected to become Chairman of the Board. Heffler said, "Inhalation Sciences is a company with a unique and very exciting technology platform that has the potential to make a huge difference to … [Read more...] about Inhalation Sciences names Lena Heffler as CEO
FDA issues revised draft guidance for MDI and DPI quality considerations
The FDA has issued a revised draft guidance, "Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Products - Quality Considerations." The guidance is scheduled for publication in the Federal Register on April 19, 2018; comments regarding the document should be submitted to the FDA within 60 days of publication. According to a draft of the Federal Register … [Read more...] about FDA issues revised draft guidance for MDI and DPI quality considerations
Insys to begin clinical research program for dronabinol inhaler
Insys Therapeutics has announced that it plans to advance clinical research of a breath activated dronabinol (THC) inhaler in the second half of 2018. The company said that it plans to develop the inhaler for the treatment of anorexia in AIDS and cancer patients and for agitation in Alzheimer's disease patients. In 2015, Insys announced that it had licensed the … [Read more...] about Insys to begin clinical research program for dronabinol inhaler
Opiant gets $7.4 million grant for development of intranasal nalmefene
According to Opiant Pharmaceuticals, the National Institutes of Health’s National Institute on Drug Abuse (NIDA) has awarded the company a 3-year grant of about $7.4 million for development of OPNT003 intranasal nalmefene for the treatment of opioid overdose. The company will receive approximately $2.6 million for the first portion of the grant funding period, which … [Read more...] about Opiant gets $7.4 million grant for development of intranasal nalmefene
Highmark and AstraZeneca sign outcomes-based agreement regarding Symbicort
US health insurer Highmark Inc. has announced that it signed an outcomes-based contract with AstraZeneca for Symbicort that provides for a rebate from AstraZeneca if the inhaler does not reduce COPD or asthma symptoms in line with clinical trial results. Highmark's evaluation of Symbicort performance will be based on "specific pharmacy and medical … [Read more...] about Highmark and AstraZeneca sign outcomes-based agreement regarding Symbicort
Penthrox methoxyflurane inhaler approved in Canada and several European countries
Penthrox, a methoxyflurane inhaler, has been approved in Canada for short-term relief of moderate to severe pain resulting from trauma or medical procedures, Medical Developments International (MDI) said. The company announced in June 2017 that its marketing authorization application had been accepted for review by Health Canada. Purdue Pharma, acquired Canadian … [Read more...] about Penthrox methoxyflurane inhaler approved in Canada and several European countries
Pulmotect raises $12 million for development of its PUL-042 inhaled immune stimulant
Pulmotect has closed on a $12 million Series B round to fund continued clinical development of its PUL-042 inhaled immune stimulant, the company said. Pulmotect has now received more than $25 million in funding for development of PUL-042, including awards of $7.1 million from Cancer Prevention & Research Institute of Texas (CPRIT) and $3 million from The National … [Read more...] about Pulmotect raises $12 million for development of its PUL-042 inhaled immune stimulant